抗GD2抗体治疗高危神经母细胞瘤的临床应用

Analysis of the clinical application of anti-GD2 antibody therapy for high-risk neuroblastoma

神经母细胞瘤是儿童最常见的颅外实体瘤。近年来根据神经母细胞瘤表面特异性抗原GD2设计了相应的靶向药物抗GD2抗体。但抗GD2抗体因毒副作用大、国内用药经验较少、药物价格昂贵等原因在临床应用时受到限制。本文通过介绍抗GD2抗体的作用机制、疗效,针对不良反应的预处理用药和成本效益分析等以期为临床用药提供参考。抗GD2抗体能显著改善神经母细胞瘤患者的长期生存质量,通过预处理用药后能提升患者对抗GD2抗体的耐受性,但该药治疗成本较高,因此只有在其价格下降的情况下,才可能成为高危神经母细胞瘤患儿的成本效益治疗选择。

Neuroblastoma is the most common extracranial solid tumor in children.In recent years,the corresponding targeting drug anti-GD2 antibody has been designed according to a tumor-specific antigen in the form of a glycolipid antigen known as GD2.However,anti-GD2 antibody has been limited in clinical application due to high toxicity and side effects,less experience in domestic use,and expensive drug price.In this paper,we introduce the mechanism of action,efficacy,pretreatment dosing for adverse reactions and cost-effectiveness analysis of anti-GD2 antibody in order to provide a reference for clinical use of the drug.Anti-GD2 antibody can significantly improve the long-term survival quality of neuroblastoma patients,and the tolerance of patients to anti-GD2 antibody can be improved by pretreatment dosing,but the treatment cost of this drug is high,so only if its price is reduced,it is possible to become a cost-effective treatment option for children with high-risk neuroblastoma.